The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 14, 2026

Filed:

Jan. 21, 2021
Applicants:

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);

University of Miami, Miami, FL (US);

Inventors:

James Mulé, Odessa, FL (US);

Rana Falahat, Tampa, FL (US);

Glen Barber, Miami, FL (US);

Assignees:

H. Lee Moffitt Cancer Center, Tampa, FL (US);

Research Institute, Inc., Miami, FL (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/7068 (2006.01); A61K 31/7084 (2006.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7068 (2013.01); A61K 31/7084 (2013.01); A61K 40/11 (2025.01); A61K 40/4272 (2025.01); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); G01N 33/5743 (2013.01); A61K 2239/57 (2023.05); C12N 2502/30 (2013.01); G01N 2333/4706 (2013.01); G01N 2333/91245 (2013.01);
Abstract

Disclosed herein is a method for enhancing antitumor T cell responses in subjects. The method involves administering to the subject in need thereof a composition comprising a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. This method is particularly useful in subjects with deficient STING expression in the tumor cells. Therefore, also disclosed is a method for treating a tumor in a subject that involves detecting in a biopsy sample from the subject reduced STING expression, reduced cGAS expression, or a combination thereof; and then administering to the subject a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. The method can further involve administering to the subject a therapeutically effective amount of a STING agonist. The method can further involve administering to the subject tumor infiltrating lymphocytes (TILs), such as HLA-matched TILs.


Find Patent Forward Citations

Mulé, James. (2026). Enhancing anti-tumor response in melanoma cells with defective sting signaling (U.S. Patent No. 12599621). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12599621

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…